1191237-41-8

Basic information

• Product Name: C₂₈H₃₂O₅
• Synonyms: C₂₈H₃₂O₅
• CAS NO: 1191237-41-8
• Molecular Weight: 448.559
• Mol File: 1191237-41-8.mol

Chemical Properties

• CAS DataBase Reference: C₂₈H₃₂O₅(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₈H₃₂O₅(1191237-41-8)
• EPA Substance Registry System: C₂₈H₃₂O₅(1191237-41-8)

Safety Data

• Hazardous Substances Data: 1191237-41-8(Hazardous Substances Data)

Upstream product

• 1191237-40-7 C₇H₁₄O₅ 
• 100-44-7 benzyl chloride 

Downstream Products

• 1314972-33-2 (3R,4R,5R)-3,4-bis(benzyloxy)-5-(benzyloxymethyl)-3-methyl-tetrahydro-furan-2-ol 
• 1191237-49-6 1′-cyano-2′-C-methyl-4-aza-7,9-dideazaadenosine 
• 1272971-35-3 2′,3′,5′-O-tribenzyl-1′-cyano-2′-C-methyl-4-aza-7,9-dideazaadenosine 
• 1191238-04-6 C₃₃H₃₅N₅O₅ 
• 1350735-69-1 C₂₉H₃₇N₆O₉P 
• 1350735-70-4 [(Sp)-isopropyl 2-((S)-(((2R,3R,4R,5R)-3-isobutyroxy-5-(4-aminopyrrolo[1,2-f][1,2,4]triazin-7-yl)-5-cyano-4-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy) (phenoxy)phosphorylamino)propanoate] 
• 1350735-68-0 (2S)-isopropyl 2-((((2R,3R,4R,5R)-3-isobutyroxy-5-(4-aminopyrrolo[1,2-f][1,2,4]triazin-7-yl)-5-cyano-4-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate 
• 1350735-57-7 (2S)-isopropyl 2-((((2R,3R,4R,5R)-5-(4-aminopyrrolo[1,2-f]-[1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate 
• 1350736-07-0 C₁₃H₁₅N₅O₄ 
• 1191237-48-5 C₃₄H₃₃N₅O₄ 
• 917567-08-9 (3R,4R,5R)-3,4-bis(benzyloxy)-5-[(benzyloxy)methyl]-3-methyloxolan-2-one 
• 1354823-59-8 (Sp)-isopropyl 2-((S)-(((2R,3R,4R,5R)-5-(4-aminopyrrolo[1,2-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate 

Relevant articles and documents

METHODS FOR TREATING HCV

This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.

METHODS FOR TREATING HCV

This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.

METHODS FOR THE PREPARATION OF DIASTEROMERICALLY PURE PHOSPHORAMIDATE PRODRUGS

Provided are methods and intermediates for preparing diastereomerically pure phosphoramidate prodrugs of nucleosides of Formulas (la) and (lb): The compounds of Formula la and lb are useful for the treatment Hepatitis C infections.

1'-SUBSTITUTED-CARBA-NUCLEOSIDE PRODRUGS FOR ANTIVIRAL TREATMENT

Provided are prodrugs of pyrrolo[l,2-f][l,2,4]triazin-7-yl nucleoside phosphates wherein the 1 '' position of the nucleoside sugar is substituted with CN. The compounds, compositions, and methods provided are useful for the treatment Hepatitis C infections.

CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT

Provided are thieno[3,4-d]pyrimidin-7-yI and furo[3,4-d]pyrimidin-7-yl ribosides, riboside phosphates and prodrugs thereof as well as intermediates and methods of preparation. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections.

CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT

Provided are imidazol [1,5-f] [1,2.4]triazinyl, imidazol [1,2,4]triazinyl, and [1,2,4] triazolo [4,3-f] [1,2,4] triazinyl nucleosides of formula I nucleoside phosphates and prodrugs thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections. Wherein X1 or X2 is indepently C-R10 or N and wherein at least one of X1 or X2 is N.